This article is from The Epoch Times and is over 2
Post# of 72447
(Total Views: 488)
Posted On: 03/16/2020 10:45:34 PM
This article is from The Epoch Times and is over 2 weeks old. If Brilacidin is found be an effective treatment for COVID-19 we will see many articles with thousands of new investors discovering our little company.
Potential Coronavirus Treatment Slated for Lab Testing
BY ZACHARY STIEBER
February 27, 2020 Updated: February 27, 2020
Innovation Pharmaceuticals on Thursday said it would soon ship a potential treatment for the new coronavirus to a regional biocontainment laboratory for testing.
The drug candidate, Brilacidin, can potentially treat the COVID-19 disease, which is caused by the new virus.
Massachusetts-based Innovation Pharmaceuticals said it signed an agreement with one of the 12 biocontainment labs in the country, which are based at universities, to research Brilacidin as a treatment for the new virus, leading to plans to ship Brilacidin to the lab in the coming days. The specific lab was not identified.
Scientists at the lab will evaluate the potential antiviral and anti-inflammatory properties of Brilacidin against viral infections, including SARS-CoV-2, the virus that causes COVID-19.
The drug candidate will be tested in some cases alongside other antivirals.
Tests could be complete within several weeks of reception of Brilacidin, Innovation said in a press release.
According to the company, Brilacidin is a versatile compound with broad therapeutic potential that’s in a new chemical class called defensin-mimetics. A Nature review article on coronaviruses suggests that immunomodulators like Brilacidin could, combined with other antivirals, be a promising treatment for the viruses, including SARS-CoV-2.
“The underlying theory is that once the viral load is reduced, the body’s natural immune response—possibly strengthened by Brilacidin administered post-infection as an adjuvant therapy—should be better able to fight off coronavirus complications,” the company said in a statement earlier in the week.
Innovation is also exploring a partnership with a government-funded virology laboratory in Asia to test Brilacidin and has submitted a preliminary summary of Brilacidin’s potential as a novel coronavirus treatment to the Biomedical Advanced Research and Development Authority.
Potential Coronavirus Treatment Slated for Lab Testing
BY ZACHARY STIEBER
February 27, 2020 Updated: February 27, 2020
Innovation Pharmaceuticals on Thursday said it would soon ship a potential treatment for the new coronavirus to a regional biocontainment laboratory for testing.
The drug candidate, Brilacidin, can potentially treat the COVID-19 disease, which is caused by the new virus.
Massachusetts-based Innovation Pharmaceuticals said it signed an agreement with one of the 12 biocontainment labs in the country, which are based at universities, to research Brilacidin as a treatment for the new virus, leading to plans to ship Brilacidin to the lab in the coming days. The specific lab was not identified.
Scientists at the lab will evaluate the potential antiviral and anti-inflammatory properties of Brilacidin against viral infections, including SARS-CoV-2, the virus that causes COVID-19.
The drug candidate will be tested in some cases alongside other antivirals.
Tests could be complete within several weeks of reception of Brilacidin, Innovation said in a press release.
According to the company, Brilacidin is a versatile compound with broad therapeutic potential that’s in a new chemical class called defensin-mimetics. A Nature review article on coronaviruses suggests that immunomodulators like Brilacidin could, combined with other antivirals, be a promising treatment for the viruses, including SARS-CoV-2.
“The underlying theory is that once the viral load is reduced, the body’s natural immune response—possibly strengthened by Brilacidin administered post-infection as an adjuvant therapy—should be better able to fight off coronavirus complications,” the company said in a statement earlier in the week.
Innovation is also exploring a partnership with a government-funded virology laboratory in Asia to test Brilacidin and has submitted a preliminary summary of Brilacidin’s potential as a novel coronavirus treatment to the Biomedical Advanced Research and Development Authority.
(9)
(0)